國壽(02628.HK)續優化投資配置抵禦減息風險
中國人壽(02628.HK)副總裁趙鵬表示,公司下半年將會繼續優化投資配置,他承認於固定資產配置方面存在困難,今年初已經提前進行相關方面配置。公司亦著重房地產投資,冀可帶來穩定現金流,目前國壽投資房地產項目36個,投資餘額超過1,000億元人民幣,項目包括境內及境外,亦有寫字樓及商業房地產。海外投資項目餘額則為120億美元。趙鵬表示,連同其他投資,冀可抵禦利率走勢向下所帶來的投資波動。
公司副總裁兼總精算師利明光表示,上半年新業務價值增長符合預期,公司將繼續重振計劃。公司副總裁詹忠亦表示,下半年將會繼續擴量計劃,在業務量及質素之間取得平衡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.